Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer 2022-02-07 08:00
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide 2022-01-14 08:00
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer 2022-01-10 21:35
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer 2022-01-04 08:00
Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program 2021-12-20 20:55
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy 2021-12-16 08:49
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea 2021-12-15 08:00
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant 2021-12-01 08:00
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index 2021-11-24 08:00
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index 2021-11-24 08:00
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint 2021-11-11 08:05
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program 2021-11-08 08:15
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program 2021-11-08 08:10
Everest Medicines Announces Share Repurchase Transaction Details 2021-11-01 08:00
Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections 2021-09-29 17:44
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206 2021-09-24 13:56
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies 2021-09-23 06:00
Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases 2021-09-17 06:30
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets 2021-09-13 17:00
Everest Medicines Announces Half-Year 2021 Interim Results 2021-08-30 22:15
1 3 4 5 6 7